SEC Form D filing

Persevere Therapeutics Inc., 2026-03-04

An SEC Form D private-offering notice from Chesterbrook, PA, a $4,999,999 filer-stated offering target in Biotech. Filed 2026-03-04. The source filing is one click away. For companies that filed this week, open the live feed.

What this filing says

Persevere Therapeutics Inc. site↗ Verified via SEC Form D

Clinical-stage oncology company developing misetionamide, a dual c-MYC/NFkB inhibitor licensed from Geistlich Pharma, for platinum-resistant ovarian cancer and other hard-to-treat tumors.

Filed 2026-03-04Filed to raise $4,999,999First money in 2026-02-11Raised so far $1,574,999HQ (as filed) Chesterbrook, PASector Biotech web-verified against the company’s own siteStage (inferred) SeedCall status Call-ready
Source linked the Form D on EDGAR↗Website verified perseveretherapeutics.com↗Named in the filing 1 executive & director
Open this row on the live feed →More new filings in Pennsylvania →More Biotech filings →

This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.

Other Form D filings from the same week

each with its own page and its own EDGAR source